Immunovant
Prix: 33.62Entreprise et modèle économique
Immunovant is a biotechnology company focused on developing innovative therapies for autoimmune diseases. Its core product is IMVT-1401, a monoclonal antibody designed to treat conditions such as myasthenia gravis. The company primarily operates in the healthcare sector, with its main revenue source being potential future sales of its therapeutic products. Immunovant is currently in the clinical development stage, with no commercialized products generating revenue.
Profil d’investissement
The investment profile of Immunovant is more aligned with growth investors due to its focus on developing new therapies and the potential for significant future revenue, albeit with high associated risks. The stock may not appeal to dividend or value investors given the lack of current profitability and established revenue streams.
Métriques fondamentales (expérimental)
- BPA (TTM) — bénéfice par action des 12 derniers mois, $
- -2.78 Risque
- Surprise BPA
- -21.7% moins bon que prévu
- Volatilité 20 j
- 8.4% normal
Impact de la prévision
neutreSuivre dans le portefeuille
Graphique des prix
| Date | Avant | Après | Raison |
|---|---|---|---|
| 2026-06-13 02:40 | Vendre | Conserver | Positive momentum, but fundamentals show significant weakness. |
| 2026-06-03 02:43 | Conserver | Vendre | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-05-22 02:48 | Vendre | Conserver | Strong recent performance, but fundamentals remain weak. |
| Date | Analyste | Action | Objectif | Prix alors |
|---|---|---|---|---|
| 2026-05-21 10:35 | H.C. Wainwright | Objectif relevé | — → 40 | 35.56 |
| 2026-01-06 12:55 | Wolfe Research | Note relevée | — → 50 | 24.97 |
| 2025-12-18 13:29 | Guggenheim | Objectif abaissé | 44 → 41 | 26.2689 |
Rien pour le moment